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Abstract
Background: Metallothionein (MT) is a cysteine-rich, metal-binding protein that can be induced
by a variety of agents. Modulation of MT levels has also been shown to alter specific immune
functions. We have noticed that the MT genes map close to the chemokines Ccl17 and Cx3cl1.
Cysteine motifs that characterize these chemokines are also found in the MT sequence suggesting
that MT might also act as a chemotactic factor.
Results: In the experiments reported here, we show that immune cells migrate chemotactically in
the presence of a gradient of MT. This response can be specifically blocked by two different
monoclonal anti-MT antibodies. Exposure of cells to MT also leads to a rapid increase in F-actin
content. Incubation of Jurkat T cells with cholera toxin or pertussis toxin completely abrogates the
chemotactic response to MT. Thus MT may act via G-protein coupled receptors and through the
cyclic AMP signaling pathway to initiate chemotaxis.
Conclusion: These results suggest that, under inflammatory conditions, metallothionein in the
extracellular environment may support the beneficial movement of leukocytes to the site of
inflammation. MT may therefore represent a "danger signal"; modifying the character of the
immune response when cells sense cellular stress. Elevated metallothionein produced in the
context of exposure to environmental toxicants, or as a result of chronic inflammatory disease,
may alter the normal chemotactic responses that regulate leukocyte trafficking. Thus, MT synthesis
may represent an important factor in immunomodulation that is associated with autoimmune
disease and toxicant exposure.
Background
Initiation of an immune response is accompanied by
physiological changes that can produce a stressful envi-
ronment for both the cells involved in the immune
response, and for bystander cells that are part of adjacent
but uninvolved tissues. These stresses can be further
increased by the presence of infectious microorganisms.
The changes to the environment include increases in reac-
tive oxygen and reactive nitrogen species, products of cel-
lular metabolism, and agents that initiate apoptotic or
necrotic cell death.
Cells react to stressful environments with a broad range of
different homeostatic responses. These responses can
include the synthesis of a host of stress response proteins,
including the heat shock proteins, acute phase cytokines,
and metallothionein. Metallothionein is a novel member
of this type of response with a unique biochemistry and
an intriguing array of physiological roles. Metallothionein
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thiols participate in complexing with divalent metal cati-
ons [2]. When metallothionein binds to essential divalent
metals (e.g. zinc and copper) it may serve as a metal reser-
voir for apoenzymes and zinc-finger transcription regula-
tors [3,4]. Metallothionein that is induced by other
divalent metal cations (e.g. mercury, cadmium,) protects
essential cellular functions [5] and enhances the survival
of both cells and whole organisms that are exposed to
toxic heavy metals. The thiol-rich nature of metal-
lothionein also enables it to regulate the redox potential
of cells, and thus serves as a way of indirectly regulating
redox-sensitive transcription via NF-kB [6]. There are also
reports that link metallothionein to a much more direct
interaction with NF-kB [7,8]. Metallothionein has also
been found to be released to the extracellular environ-
ment in a number of different compartments, including
cell culture media, serum, urine, bronchoalveolar spaces,
liver sinusoids, and inflammatory lesions [9-12]. Extracel-
lular metallothionein has been shown to have significant
immunomodulatory effects both in vivo and in vitro [13-
16] however the molecular mechanism(s) of this effect
have yet to be elucidated.
Leukocyte movement is an essential component of the
normal response to inflammatory signals. A variety of
chemotactic agents can be produced by local immune
cells, damaged bystander cells, and by invading microor-
ganisms. In aggregate, these soluble signals determine the
infiltration and departure of cells that participate in the
inflammation, and serve as essential regulatory compo-
nents of the immune response. Stress responses alter these
patterns of leukocyte trafficking in various ways. For
example, psychological stress in humans has been shown
to increase both the magnitude of the cellular influx at an
inflammatory site and the chemotactic index of peripheral
blood mononuclear cells [17]. Restraint stress in hamsters
has similarly increased leukocyte trafficking and delayed
type hypersensitivity responses [18]. Xenobiotics may
alter leukocyte trafficking in similar ways to diminish
immune competence.
We have found that metallothionein has significant
chemotactic activity for both cell lines and primary leuko-
cytes. For most of the work described in this report we
have used a new assay of chemotactic cell movement. The
ECIS/taxis assay is sensitive enough to detect the response
of a single cell, and allows automated, real-time quantifi-
cation of cell movement (21). These results suggest that
cell movement in stressful environments may be influ-
enced by the presence of metallothionein, and that this
protein could be an important therapeutic target for the
manipulation of inflammation in vivo.
Results
Cysteines present in the primary amino acid sequence of
metallothionein are arranged in cys, cys-cys, cys-X-cys,
and cys-X3-cys motifs. These motifs are also found in
chemokine molecules, and serve to differentiate chemok-
ine families from one another. A comparison of the
sequences of metallothionein and the chemokine Ccl17 is
shown in Figure 1A. In addition to having similar cysteine
motifs, Ccl17 is also located near the MT genes in both
mice and humans (Figure 1B). Combined with our previ-
ously published observations of the impact extracellular
metallothionein has on developing T-dependent humoral
immunity [15] information suggested that metal-
lothionein might display chemotactic activity.
Naïve splenocytes and thioglycollate-elicited leukocytes
respond chemotactically to metallothionein in the
Boyden chamber assay at a level similar to that observed
when the cells are exposed to guinea pig serum used as a
source of activated complement (Figure 2A). To avoid the
heterogeneity of primary cell populations, the chemotac-
tic dose response of cells to metallothionein was charac-
terized using Jurkat T cells. Previous studies have shown
that these T cells express CXCR4 (the stromal derived fac-
tor-1α (SDF-1α) receptor), and exposure to an SDF-1α
gradient has previously been shown to induce a chemo-
tactic response [19]. Using the Boyden chamber assay, we
found that these cells also respond to metallothionein
(Figure 2B) in a dose-dependent manner. The dose
response curve shows a peak response at 14.3 µM, and the
shape of the curve is consistent with that of other chem-
okines [20].
In addition to the Boyden chamber assay, chemotaxis was
assessed using a recently developed technology called
ECIS/taxis. This assay employs a miniature under-agarose
chemotaxis chamber in which cell arrival on a surface
microelectrode is measured by changes to electrical cur-
rent flow through the electrode [21]. Unlike the Boyden
chamber assay, the under-agarose configuration allows
the establishment of stable and shallow chemotactic gra-
dients that more accurately reflect the subtle gradients
found in vivo than the Boyden chamber assay. In ECIS/
taxis measurements, the total normalized resistance to
current flow is proportional to the number of cells that
occupy the surface of the target electrode. If no chemoat-
tractant is added, few cells move out of the well and those
that do never reach the target electrode and no change in
resistance is recorded (Figure 3). In the presence of a gra-
dient of metallothionein, the initial arrival of a small
number of cells at the target electrode is indicated by the
appearance of small, rapid resistance fluctuations. Over
time as more cells accumulate on the electrode, a gradual
increase in resistance is observed. The concentration of
metallothionein added to the chemoattractant well thatPage 2 of 12
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BMC Immunology 2005, 6:21 http://www.biomedcentral.com/1471-2172/6/21Structural features of metallothionein gene and proteinFigure 1
Structural features of metallothionein gene and protein. A: Clustal alignment of Ccl17 and metallothionein (MT) pro-
tein sequences. Amino acid similarity is set at 85% (gray). Identical amino acids are boxed. B: Mouse chromosome 8 showing 
expanded region from map position 43 to 47 shown on left. Homologous human genes and their chromosomal map positions 
are indicated on the right. Synteny map generated by the Mouse Genome Database [63].Page 3 of 12
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Chemotactic responses of cells to metallothionein in the modified Boyden chamber assay. A. Mouse splenocytes 
or Thioglycollate-elicited cells respond to guinea pig serum (as a source of activated complement) and to metallothionein. Cells 
that had migrated to the lower side of the filters were counted in at least six fields of view per well. Data are means of six fields 
in each of six replicates. The data shown is representative of three experiments and is expressed as the average ± standard 
deviation. B. Dose response curve of chemotaxis to metallothionein. Different concentrations of metallothionein were loaded 
into the lower wells of the Boyden chambers and Jurkat T cells were added to the upper wells.Page 4 of 12
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fastest movement of responding Jurkat T cells (data not
shown) was 14.3 µM. This dose optimum is similar to that
measured with the Boyden chamber assay. The average
speed of the fastest Jurkat T cells, 1.56 ± 0.12 µm/min, was
calculated from the time of arrival of the first cells at the
target electrode. This speed is comparable to the speed of
the Jurkat T cell response to a gradient of SDF-1α (1.43 ±
0.1 µm/min, Figure 3). We also tested metallothionein's
effect on WBC 264-9C cells. These cells have been shown
to exhibit chemotactic movement toward a source of acti-
vated complement [22]. In the ECIS/taxis assay, WBC
264-9C cells are chemotactic toward both activated com-
plement and metallothionein (Figure 4). The metal-
lothionein response was dose-dependent, and the
optimal dose was similar to that found with Jurkat T cells
(data not shown). The average speed of WBC 264-9C cells
responding to a gradient of guinea pig serum used as a
source of activated complement was 1.32 ± 0.2 µm/min,
compared to 0.75 ± 0.03 µm/min for cells responding to
metallothionein. However, the population response was
nevertheless robust since total resistance (indicating the
absolute number of responding cells) ultimately reached
a level that approximates that produced by cells respond-
ing to activated complement.
In light of the potential for contaminants (e.g. small liver
peptides that co-purify with the MT) in the commercially
available metallothionein preparations, we affinity-puri-
fied metallothionein from commercial preparations using
an anti-metallothionein monoclonal antibody (UC1MT)
coupled to CNBr-activated Sepharose. The purified metal-
lothionein also stimulates Jurkat T cell chemotaxis (Figure
5A). In addition, the chemotactic response to the original
metallothionein (data not shown) or the affinity-purified
metallothionein (Figure 5A) could be blocked by pre-
incubation of the purified metallothionein with either
UC1MT or E9 monoclonal anti-metallothionein
Dose response of Jurkat T cells to metallothionein measured by ECIS/taxisFigure 3
Dose response of Jurkat T cells to metallothionein measured by ECIS/taxis. Jurkat T cells were added to the cell 
wells and the indicated chemoattractant was loaded into the opposing well. SDF-1α is used as a positive control. The resist-
ance measured at the electrode between the two wells is shown. Inset: A 3 hour window of data on an expanded scale is 
shown to highlight the arrival of cells on the electrode. Arrows indicated the time of arrival of the first cells leading to the 
appearance of small fluctuations in resistance.Page 5 of 12
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bodies nor the isotype-matched IgG1 (MOPC 21) stimu-
lated cell movement to the target electrode on their own
(data not shown).
G protein activation has been shown to play a role in the
chemotactic response and this pathway can be inhibited
by cholera toxin (CTX) [23] or pertussis toxin (PTX)
[24,25]. Jurkat T cells (106 cells/ml) were pre-incubated
with 0.133 µg/ml CTX or 200 ng/ml pertussis toxin and
then placed in a metallothionein gradient. The chemotac-
tic effect of metallothionein on Jurkat T cells could be
blocked by CTX (figure 5B) and by PTX (figure 5C). PTX
was also capable of blocking the chemotaxis of Jurkat cells
to SDF-1α.
A more direct assessment of chemotaxis was done using
time-lapse video microscopy of cells moving in the pres-
ence of a metallothionein or SDF-1α gradient. When Jur-
kat T cells were exposed to a gradient similar to that
present in the ECIS/taxis assay, they could be observed to
move out of the cell well and continue up the gradient
toward the chemoattractant well. Tracks of the outlines of
these cells show persistent directional movement (Figure
6D, E). In the absence of a gradient few cells exit the cell
well (data not shown), and those that do show little
directional movement (Figure 6A–C). The speed, persist-
ence and chemotactic indices of individual cell move-
ments are consistent with the speeds calculated using the
ECIS/taxis measurements of population movement
(Table 1). In order to assess the role of chemokinesis in
this process, cells were overlaid with a pre-formed agarose
sheet containing a uniform concentration of metal-
lothionein, SDF-1α or medium alone. The MT-exposed
cells moved more rapidly than control cells, but the move-
ment lacked directional persistence and was much slower
than movement in a spatial gradient (Table 1 and Figure
6A–C). Similar results were obtained using a checker-
board analysis of cell movement in the Boyden chamber
format (Table 2). Metallothionein added to the same side
of the filter as the cells, or to both sides of the filter in
equal concentration resulted in fewer cells reaching the
lower surface of the filter than in wells where the metal-
lothionein was added to the opposite side of the filter
from the cells. This data supports the conclusion that met-
allothionein induces both chemotaxis and chemokinesis
in Jurkat T cells.
Another hallmark of cellular responses to chemokines is a
change in the amount and distribution of polymerized
actin. Signal transduction through G protein coupled
receptors causes reorganization of the actin cytoskeleton,
leading to the formation of new F-actin rich lamellipods
that extend in the direction of movement. This reorgani-
zation can be assessed by in vitro measurements of
polymerized actin from cell extracts of stimulated cells
with phalloidin [26]. Metallothionein stimulated a 19%
increase in total F-actin within 30 seconds and a 79%
increase by 2 minutes (Figure 7). The extent and timing of
this response is consistent with receptor activation in
other cell types [27,28].
Discussion
Cells of the immune system operate in a complex micro-
environment where they are presented with a host of dif-
ferent and often conflicting signals [29,30]. The ways in
which cells integrate and respond to these signals can ulti-
mately govern the way in which the immune system will
respond to antigen exposure. In some cases, the outcome
is an activated immune response that is designed to elim-
inate the source of antigen. In other instances, the cells
become anergic or undergo apoptosis and thus fail to ini-
tiate or participate in an immune response to that antigen.
An early aspect of many immune responses is the direc-
tional movement of cells toward a site of infection or
other injury. This directional movement is a response to
chemotactic factors produced by some infectious organ-
isms, to chemokines produced by cells already at the site
of inflammation, or to other agents. Cells that express
receptors for these signals can detect the gradient(s) of
diffusing chemoattractants, and move toward the source
ECIS/taxis assessment of the chemotactic response by WBC 264-9C cellFigure 4
ECIS/taxis assessment of the chemotactic response 
by WBC 264-9C cells. Cell wells were loaded and guinea 
pig serum (1:2 dilution), PBS, or 20 µM metallothionein was 
added to the chemoattractant wells. Serum complement is 
activated by exposure to agarose to generate a control 
chemotactic gradient. Inset: A 3 hours window of data on an 
expanded scale showing the arrival of cells on the electrode.Page 6 of 12
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aspect of lymphocyte trafficking.
In this report, we show that metallothionein can direct the
chemotaxis of primary and transformed leukocytes. While
metallothionein has been historically thought of as an
intracellular protein, there are numerous reports that
describe its presence in serum, urine [31], broncho-alveo-
lar spaces [10], liver sinusoids [32], and other extracellular
locations. While the mechanism(s) by which metal-
lothionein is released from cells has yet to be determined,
heat shock protein 70 [33], Interleukin 1β [34] and
fibroblast growth factor [35] are among a set of proteins
that lack signal sequences and nevertheless are released
from cells by a non-traditional secretory mechanism.
These results indicate that stress response proteins may
gain access to the extracellular environment via
mechanisms other than cell lysis, and suggest that a thor-
ough understanding of the immunomodulatory roles
played by metallothionein must include the extracellular
compartment.
Metallothionein is synthesized in response to acute phase
cytokines (e.g. IL-1, IL-6, and TNF-a) that are secreted at
sites of inflammation [36-38] in a variety of contexts in
which immune activities are changing. Metallothionein is
also synthesized in cells exposed to glucocorticoids, a sig-
nal that is often associated with stressful environments
[39]. Furthermore, metallothionein can be induced by
reactive oxygen species, by endotoxin [40], and in cells
exposed to divalent metal cations [1]. With all of these dif-
ferent initiators, it is not surprising that elevated metal-
lothionein levels are detected in the context of neoplastic
disease [41,42], autoimmune disease [43], chronic
inflammation [44], and infection [45]. Previous work
from our laboratory and others has shown that metal-
lothionein can have significant immunomodulatory
activities. For example, metallothionein can diminish T
dependent humoral responses and it can alter the prolif-
erative capacity of lymphocytes [16], diminish cytotoxic T
cell function [46], and it can alter the effector function of
macrophages [47]. Inadequate expression of
metallothionein in the context of inflammatory disease
can dramatically shorten life span [43], and exogenous
Table 1: DIAS analysis of chemokinetic and chemotactic movement. Jurkat T cells were cultured under agarose in the presence of 
uniform concentrations or in a gradient of the stimuli. Cells were imaged over time and their motile behavior quantified. Persistence 
is an indicator of the rate of directional change. Chemotactic index is a measure of the proportion of movement in a designated 
direction (1 = toward a source, 0 = random movement, -1 = away from the source).






Media control (7) 0.66 ± 0.29 0.18 ± 0.11 0.19
Uniform concentration of metallothionein (10) 2.110 ± 0.73 0.5 ± 0.22 0.07
Uniform concentration of SDF-1α (10) 1.69 ± 0.82 0.53 ± 0.34 0.09
Metallothionein gradient (7) 6.6 ± 3.2 2.042 ± 1.09 0.73
SDF-1α gradient (7) 3.31 ± 1.48 1.17 ± 0.49 0.72
Table 2: Checkerboard analysis of chemokinetic cell movement induced by metallothionein. Metallothionein has both chemokinetic 
and chemotactic activities. Significant chemotactic movement is measured when metallothionein is presented from below the filter. 
Chemokinetic movement is indicated when metallothionein is present above the filter, or in both chambers. The data is 
representative of three independent experiments.
Cell number migrated to lower side of membrane
Metallothionein (µM) above filter
Metallothionein (µM) 
below filter
0 2.5 5.0 10
0 14.0 ± 4.3 90.8 ± 17.5 43.0 ± 3.2 20.6 ± 9.2
2.5 55.3 ± 17.0 61.3 ± 23.9 38.7 ± 12.5 25.5 ± 13.2
5.0 192.8 ± 45.4 93.6 ± 20.1 67.0 ± 12.5 37.0 ± 12.1
10 80.2 ± 23.7 96.0 ± 21.8 68.0 ± 21.2 30.8 ± 10.3Page 7 of 12
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induced arthritis [48].
There are a multitude of studies which show that different
forms of stress originating from external sources can alter
normal immune function [49]. Psychological, physical
and chemical agents which induce stress each affect the
immune system. In some instances, these stressors sup-
press effective immune functioning, which renders the
individual susceptible to infectious pathogens. In other
instances, the immune modifications result in undesira-
ble increases in immune recognition of self antigens, ulti-
mately resulting in autoimmune disease. These stressors
are known to induce metallothionein synthesis and may
alter immune functions in part via their effect on
metallothionein.
We have demonstrated metallothionein-induced chemo-
tactic cell movement in the traditional Boyden chamber
assay, by computerized analysis of time-lapse images of
cell movement, and using the ECIS/taxis assay. We have
shown that the response of Jurkat T cells to a metal-
lothionein gradient corresponds well with chemotactic
responses of leukocytes to other agents. Jurkat T cells and
WBC 264-9C migrate in response to a metallothionein
gradient at speeds which are similar to those found in
other systems [50,51]. In addition, the pattern of the dose
response to metallothionein is a bell shaped curve similar
to other classical chemokines [20]. One important consid-
eration is whether the chemotactic response to metal-
lothionein occurs at physiologically relevant
concentrations. Chemoattractants can act over an
extremely wide concentration range (e.g. 4 logs) [52,53]
because the cells sense the local spatial differential in che-
moattractant concentration. Our work shows that 1 to 10
µM metallothionein can stimulate chemotaxis of cells in
both Boyden and under-agarose assays. Higher
concentrations of metallothionein used in the ECIS/taxis
assay refer to the concentrations added to the micro-vol-
ume chemoattractant wells, which are then diluted in the
process of diffusion away from the source. The metal-
lothionein amounts used in these experiments represent
biologically reasonable concentrations, given that metal-
lothionein has been measured at concentrations of 1 µM
in serum (which would be substantially diluted from the
source tissue concentration) in normal patients, and in
individuals undergoing some form of stress (inflamma-
tion, cancer, toxicant exposure, etc.) [54].
The chemotactic response to metallothionein can be
blocked by monoclonal antibodies to metallothionein
while isotype-matched antibody has no effect. This block-
ade of the response is an important control, since com-
mercial metallothionein preparations contain
contaminating peptides from the liver tissue source (D.
Lawrence, personal communication). Since both cholera
Inhibitors of MT chemotaxisFigure 5
Inhibitors of MT chemotaxis. A: Monoclonal anti-metallothionein antibody blocks the chemotactic response of Jurkat T 
cells to 20 µM metallothionein gradient. Affinity-purified metallothionein (20 µM) was incubated with antibody (clone UC1MT 
or E9) and then added to the chemoattractant well. Controls were performed with metallothionein alone (MT), medium alone 
(-), or metallothionein preincubated with isotype-matched control antibody (not shown). B: Cholera toxin (CTX) inhibits 
chemotactic response to metallothionein. Jurkat T cells were preincubated with or without 0.133 µg/106 cells/ml CTX at 37°C 
for 1 h and then added to the cell well. Chemotactic responses of toxin-treated cells to MT (CTX-MT) were compared to 
untreated cells (MT) and untreated cells without an MT gradient (-). C: Pertussis toxin (PTX) blocks the chemotactic response 
to metallothionein. Jurkat T cells were preincubated with or without 200 ng/106 cells/ml PTX at 37°C for 16 h. Chemotactic 
responses of toxin-treated cells to MT (PTX-MT) was compared to untreated cells (MT) and untreated cells without an MT 
gradient (-). Each figure is a representative more than four independent experiments performed in triplicate.Page 8 of 12
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ated chemotaxis, it is likely that G protein mediated sign-
aling is involved in the response. Another common aspect
of chemotactic signaling is an activation of the actin
polymerization machinery in response to a sharp increase
in chemoattractant concentration [26,55]. Metal-
lothionein causes an increase both in total F-actin content
and in peripheral F-actin. It will be of great interest to
determine the receptor for metallothionein and the signal
transduction pathway that leads to actin polymerization.
It is intriguing to speculate that once outside the cell, met-
allothionein serves as one of the many signals designed to
draw immunocompetent cells to sites of cellular stress.
Our observation(s) that metallothionein and anti-metal-
lothionein injections modify immune activity in vivo sug-
gest that there is an appropriate range of extracellular
metallothionein in which leukocytes ordinarily function
[14,15]. A pair of recent reports suggest that cytosolic con-
stituents of apoptotic cells are released to the extracellular
compartment and support the progression of the inflam-
matory process [56,57]. These reports further suggested
that release of the cytosolic components of these dying
cells might represent one of the signals central to the
"Danger Hypothesis" proposed by Matzinger et al.
[58,59]. This hypothesis holds that an active immune
response cannot be mounted without a signal indicating
that cellular damage has occurred. While other reports
have suggested that heat shock proteins can fill this role




Jurkat T cells, (TIB-152, American Type Culture Collection
(ATCC), Bethesda, MD) were maintained in complete
RPMI 1640 media with L-glutamine containing 10% heat-
inactivated FBS (Mediatech, Herndon, VA), 1% Sodium
Bicarbonate, 100 units/ml penicillin, 0.1 mg/ml strepto-
mycin, 1% sucrose, and 1 mM sodium pyruvate as recom-
mended by ATCC. WBC 264-9C cell lines (HB-8902,
ATCC) were kept in Minimum Essential Medium (Eagle)
with Earle's balanced salt solution (BSS) containing 10%
heat-inactivated fetal bovine serum. All cells were cultured
in a humidified incubator with 5% CO2 in air at 37°C.
The WBC 264-9C is a macrophage-like cell line that is
chemotactic to N-formylmethionyl-leucyl-phenylalanine
[61]. Media was replenished every three days.
Cell movement in the presence and absence of metal-lothionein and SDF-1αFigure 6
Cell movement in the presence and absence of met-
allothionein and SDF-1α. Images at 3 minute intervals 
(over a 75 minute time period) are presented for untreated 
cells (A), cells treated with a uniform concentration of 
MT(0.5 µM) (B), or SDF-1α (100 ng/ml) (C), or cells moving 
under agar in a chemotactic gradient of MT (20 µM) (D) or 
SDF-1α (200 ng/ml) (E). Each panel has the same number of 
images and represents the same total time interval. The line 
at the bottom of panels D and E represents the direction of 
the chemoattractant gradient from high (wide) to low (nar-
row). Only cells that have exited the cell well and are clearly 
visible under the agarose were analyzed.
Actin reorganization in metallothionein-stimulated cellsFigure 7
Actin reorganization in metallothionein-stimulated 
cells. Jurkat T cells were treated with metallothionein at 2 
µM and then harvested and fixed at various times after stim-
ulation. Cells were stained with rhodamine phalloidin and F-
actin fluorescence quantified using a plate fluorimeter. (RFU 
= relative fluorescent units). Values reported represent the 
average of 3 replicates ± standard deviation. *** represents 
significant difference from the medium alone control (p < 
0.001). This data is representative of 3 independent 
experiments.Page 9 of 12
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SDF-1α (Synthetic Human SDF-1α) was purchased from
BD Biosciences (Bedford, MA). BSA (DNase, RNase, and
Protease-free) and Hema-3 stain set kit were purchased
from Fisher Scientific Inc. (Pittsburgh, PA). A mixture of
Cd, Zn-metallothionein I and II purified from rabbit liver,
mouse IgG1, kappa (MOPC21) purified immunoglobulin,
and pertussis toxin, were purchased from Sigma Chemical
Co. (St Louis, MO). SeaKem® GTG® Agarose was obtained
from BioWhittaker Molecular Applications (Rockland,
ME). Metallothionein monoclonal antibodies UC1MT
(IgG1, kappa) [14,15], available from StressGen, Inc., Vic-
toria, BC and E-9 (IgG1, kappa), purchased from Zymed
Laboratories Inc. (San Francisco, CA) were used in some
experiments. Cholera toxin was purchased from List Bio-
logical Laboratories, Inc. (through Cedarlane, Ltd.,
Hornby, ONT Canada). Guinea pig serum was purchased
from Colorado Serum Company (Denver, CO).
Affinity purification of metallothionein
UC1MT was first purified on ProteinG-Sepharose (Sigma)
according to manufacturer's instructions. The purified
antibody was then coupled to CNBr-activated Sepharose
(Sigma) according to manufacturer's instructions. Metal-
lothionein I and II, prepared in PBS, was mixed with the
immobilized UC1MT and allowed to bind. After
unbound proteins were washed away from the affinity
matrix, the specifically captured protein was eluted with
0.1 M glycine HCl, pH 2.8, adjusted pH to 7.4 and dia-
lyzed against PBS.
Boyden chamber assay
The micro-Boyden assay was done using a 48 well cham-
ber apparatus (NeuroProbe, Cabin John, MD). Polyvi-
nylpyrrolidone (PVP)-free polycarbonate membrane
filters with 5 µm pores were obtained from the same
source. The lower chambers of the apparatus were loaded
with 30 µl of diluted chemoattractant in media, PBS vehi-
cle in media, or media alone and then covered with the
membrane and the upper chambers. Fifty microliters of
cell suspension (2 × 106 cells/ml) was then added to the
upper chambers. After incubating for 2 hours in a humid-
ified incubator at 37°C in 5% CO2, the filters were col-
lected, cells that remained on the upper surface of the
filter were removed and the filters were processed accord-
ing to manufacturer's instructions. The numbers of
migrated cells were counted under 400× magnification.
For each of six replicate wells, the numbers of cells in at
least six fields were determined and the mean and stand-
ard deviation was calculated.
ECIS/taxis assay
This assay was done as previously described with minor
modifications [21]. Linear electrode ECIS chambers
(Applied Biophysics, Inc. Troy, NY) were used in the
assays described here. Target electrodes were 0.02 × 2 mm,
and were used in an orientation in which the long axis of
the target electrode was oriented perpendicularly to the
direction of cell migration. All the chambers containing
electrodes were pre-treated with 10 mM cysteine for 15
min at room temperature to stabilize the electrical per-
formance of the gold electrodes, washed three times with
sterile distilled water, and dried in a standard biosafety
laminar-flow hood. Then 250 µl of molten 0.5% agarose
gel (dissolved in RPMI 1640 with 10% FBS) was added to
each chamber and allowed to cool. Two wells were cut
with a sharpened 14 gauge cannula equally distant on
either side of the electrode and separated a combined
intrawell distance of approximately 1.9 to 2 mm. Then 7
µl of cell suspension (15 × 106 cells/ml for Jurkat T cells
and 10 × 106 cells/ml for WBC 264-9C cells) was placed
into the cell well and an equal volume of chemoattractant
or vehicle control was dispensed into the opposite well. A
1 volt AC current of 4000 Hz is passed through the elec-
trode, and the resistance of the circuit was calculated. Cell
movement was assessed by measurements of changes in
the resistance caused by arrival of cells at the target elec-
trode. Data is reported as the change in resistance at the
target electrode normalized to the initial resistance of the
system. In addition to the general increase in resistance
caused by cells covering the electrode, rapid fluctuations
in resistance are indicative of changes in the shape and
surface adherence of cells, and of continuing cell viability
and movement.
Trough chemotaxis assay
For some chemotaxis experiments,3.5 ml of 0.5% agarose
(dissolved in medium with 10% FBS and 20 mM HEPES)
was loaded into a 35 mm Petri dish. After the agarose
solidified, 2 wells separated by about 2 mm were cut in
the agarose. One well was loaded with 7 µl of chemoat-
tractant or media and the opposing well was loaded with
7 µl of cell suspension. The Petri dish was then sealed with
Parafilm to retain moisture and incubated on the micro-
scope stage at 37°C. Temperature was maintained by
enclosing the microscope in a Styrofoam box in which a
constant temperature airstream was provided by an Air-
Therm feedback regulated heater (WPI, Inc., Sarasota FL).
Chemokinesis in the under-agarose environment was
investigated by seeding cells to the surface of the Petri dish
in liquid media. After the cells had settled, the overlying
media was removed and the cells were overlaid with a pre-
gelled layer of agarose containing a uniform concentra-
tion of the different stimuli or medium alone. Images of
the cells were taken at regular intervals using a CCD-72
analog video camera (Dage, Michigan City, IN) and Scion
frame grabber controlled by Scion Image (Scion, Inc., Fre-
derick, Maryland) software. The images were compiled
into movies using public domain Image J software [62].
The trajectories of cells were analyzed from these moviesPage 10 of 12
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(Solltech, Inc., Oakdale, IA). Trajectories of a number of
cells from each condition (see n in table 1) were tracked
and analyzed from the movies. Each cell was tracked for
the same total time interval and the data is presented as
the mean of all cells analyzed.
Measurements of actin polymerization: Cells were spun at
200 × g for 5 minutes and resuspended in RPMI 1640 con-
taining 10% FBC at a density of 2 × 106 cells/ml. Cells
were stimulated with either SDF-1α (data not shown) or
2 uM metallothionein at 37°C and then fixed with 3.7%
formaldehyde for 15 minutes in Buffer F on a rotator at
room temperature (5 mM KCl, 138 mM NaCl, 4 mM
NaHCO3, 0.4 mM KH2PO4, 1.1 mM Na2HPO4, 2 mM
MgCl2, 2 mM EGTA, 5 mM PIPES, pH 7.2). The fixed cells
were centrifuged and resuspended in 1 ml of 0.5% Triton
X-100 in Buffer F for 20 minutes and stained in 1 uM
TRITC-Phalloidin in Buffer F on a rotator for 1 hour at
room temperature. They were then pelleted, washed with
5 ml Buffer F twice, and re-suspended in 850 µl of Buffer
F. The TRITC-Phalloidin fluorescence in the cell
suspension was measured using a Spectramax M2 fluor-
imeter (Molecular Devices, Sunnyvale, CA) at 544 nm
excitation and 580 nm emission. In each well, the raw
fluorescence of 9 points were measured and used to calcu-
late the average well fluorescence.
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